Key points are not available for this paper at this time.
his review focuses on the postulated mechanism underlying elevation of erythropoietin, hemoglobin, and hematocrit levels in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 (SGLT2) inhibitors and how this phenomenon is linked to reduced progression of chronic kidney disease, lower mortality, and a lower risk of heart failure hospitalization.
Sano et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: